Oral contraceptives and hernostasis

References

• Winkler U. H. Menopause, hormone replacement therapy and cardiovascular disease: a review of hemostaseological findings. Fibrinolysis 1922; 6(Suppl. 3)5–10
   Google Scholar
• Fruzzetti F., Ricci C., Fioretti P. Haemostasis profile in smoking and nonsmoking women taking low-dose oral contraceptives. Contraception 1994; 49: 579–92
   PubMed Web of Science ®Google Scholar
• Girolami A., Paolo S., Bruno G., Luigi S. Oral contraceptive therapy causes an increased and not a decreased resistance to APC. Blood Coagul. Fibrinol. 1994; 6: 143–4
   Google Scholar
• Vandenbroucke J. P., Koster T., Briët E., Reitsma P. H., Bertina R. M., Rosendaal F. R. Increased risk of venous thrombosis in oral contraceptive users who are carriers of factor V Leiden mutation. Lancet 1994; 344: 1453–7
   PubMed Web of Science ®Google Scholar
• Rees D. C., Cox M., Clegg J. B. World distribution of factor V Leiden. Lancet 1995; 346: 1133–4
   PubMed Web of Science ®Google Scholar
• Pabinger I., Schneider B., and the GTH Study Group on Natural Inhibitors. Thrombotic risk of women with hereditary Antithrombin III-, Protein C- and Protein S-deficiency taking oral contraceptive preparation. Thromb. Haemostas. 1994; 71: 548–52
   PubMed Web of Science ®Google Scholar
• Spek C. A., Koster T., Rosendaal F. R., Bertina R. M., Reitsma P. H. Genotype variation in the promotor region of the protein C gene is associated with plasma protein C levels and thrombotic risk. Arterioscler. Thromb. Vasc. Biol. 1995; 15: 214–18
   PubMedGoogle Scholar
• Huisveld L. A., Hospers J. E. H., Meijers J. C.M., Starkenburg A. E., Erich W. B. M., Bouma B. M. Oral contraceptives reduce total protein S, but not free protein S. Thromb. Res. 1987; 45: 109–14
   Google Scholar
• Daume E. Influence of modem low-dose oral contraceptives on hemostasis. Adv. Contracept. 1990; 6: 51–68, (Suppl.)
   PubMedGoogle Scholar
• Koster T. Deep-Vein Thrombosis. A population-based case—control study. Leiden Thrombophilia Study. Thesis Leiden University. 1995
   Google Scholar
• Kluft C. Disorders of the haemostatic system and the risk of development of thrombotic and cardio-vascular diseases: limitations of laboratory diagnosis. Am, J. Obstet. Gynecol. 1990; 163: 305–12
   PubMed Web of Science ®Google Scholar
• Pedersen O. D., Munkvad S., Gram J., Kluft C., Jespersen J. Depression of factor XII-dependent fibrinolytic activity in survivors of acute myocardial infarction at risk of reinfarction. Eur. Heart J. 1993; 14: 785–9
   Google Scholar
• Fowkes F. G. R., Lowe G. D. O., Housley E., Rattray A., Rumley A., Elton R. A., MacGregor I. R., Dawes J. Cross-linked fibrin degradation products, progression of peripheral arterial disease, and risk of coronary heart disease. Lancet 1993; 342: 84–6
   PubMed Web of Science ®Google Scholar
• Ridker P. M., Hennekens C. H., Cerskus A., Stampfer M. J. Plasma concentration of cross-linked fibrin degradation products (D-dimer) and the risk of future myocardial infarction among apparently healthy men. Circulation 1994; 90: 2236–40
   PubMed Web of Science ®Google Scholar
• Thompson S. G., Kienast J., Pyke S. D.M., Haverkate F., van de Loo J. C.W., for the European Concerted Action on Thrombosis and Disabilities, Angina Pectoris Study Group. Hemostatic factors and the risk of myocardial infarction or sudden death in patients with angina pectoris. N. Engl. J. Men. 1995; 332: 635–41
   PubMed Web of Science ®Google Scholar
• Fowkes F. G. R., Connor J. M., Smith F. B., Wood J., Donnan P. T., Lowe G. D.O. Fibrinogen genotype and risk of peripheral atherosclerosis. Lancet 1992; 339: 693–6
   PubMed Web of Science ®Google Scholar
• Bara L., Nicaud V., Tiret L., Cambien F., Samama M. M., on behalf of the EARS group. Expression of a paternal history of premature myocardial infarction on fibrinogen, Factor VIIc and PAI-1 in European offspring - the EARS study. Thromb. Haemostas. 1994; 71: 434–40
   PubMedGoogle Scholar
• Eriksson P., Kallin B., van 't Hooft F. M., Bavenholm P., Hamsten A. Allele-specific increase in basal transcription of the plasminogen-activator inhibitor 1 gene is associated with myocardial infarction. Proc. Natl. Acad. Sci. USA 1995; 92: 1851–5
   PubMed Web of Science ®Google Scholar
• Ridker P. M., Hennekens C. H., Lindpaintner K., Stampfer M. J., Eisenberg P. R., Miletich J. P. Mutation in the gene coding for coagulation factor V and the risk of myocardial infarction, stroke, and venous thrombosis in apparently healthy men. N. Engl. J. Med. 1995; 332: 912–17
   PubMed Web of Science ®Google Scholar
• Van der Bom J. G., de Knijff P., Bots M. L., Haverkate F., Hofman A., Kluft C., Grobbee D. E. Polymorphism of the blood clot lysis enzyme tissue-type plasminogen activator is associated with myocardial infarction. Circulation 1995; 92(Suppl. I)30–1
   Google Scholar
• Bloemenkamp K. W.M., Gevers Leuven J. A., Helmerhorst F. M., Dersjant-Roorda M. C., de Boer R., Meijer P., Spielmann D., Kluft C. In low-dose oral contraceptives containing 20 μg or 30 μ g ethinylestradiol, gestodene is associated with a lower increase in coagulant factor VII than is desogestrel. Gynecol. Endocrinol. 1996; 10(Suppl. 2)145–8
   Google Scholar
• Task force on oral contraceptives. A multicentre study of coagulation and haemostatic variables during oral contraception: variations with four formulations. Br. J. Obstet. Gynaecol. 1991; 98: 1117–28
   PubMedGoogle Scholar
• Abbate R., Pinto S., Rostagno C., Bruni V., Rosati D., Mariani G. Effects of long-term gestodene-containing contraceptive administration on hemostasis. Am. J. Obstet. Gynecol. 1990; 163: 424–30
   PubMed Web of Science ®Google Scholar
• Morrissey J. H. Tissue factor interactions with factor VII: measurement and clinical significance of factor Vila in plasma. Blood Coagul. Fibrinol 1995; 6(Suppl. 1)S14–S19
   Google Scholar
• Jespersen J., Kluft C. Increased euglobulin fibrinolytic potential in women on oral contraceptives low in oestrogen. Levels of extrinsic and intrinsic plasminogen activators, prekallikrein, factor XII, and C1-inactivator. Thromb. Haemostas. 1985; 54: 454–9
   PubMed Web of Science ®Google Scholar
• Kluft C. Fibrinolysis risk markers for cardiovascular disease. Gynecol. Endocrinol 1993; 7: 45–53, (Suppl.)
   Google Scholar
• Kluft C., Gevers Leuven J. A., Helmerhorst F. M. Studies on the mechanisms of action of steroids on coagulation and fibrinolysis. Sex Steroids and the Cardiovascular System, P. Ramwell, G. Rubanyi, E. Schillinger. Schering Foundation Workshop 5, Springer, Berlin 1992; 95–110
   Google Scholar
• Gevers Leuven J. A., Kluft C., Dersjant-Roorda M. C., Harthoorn-Lasthuizen E. J., de Boer R., Helmerhorst F. M. Effects of low dose oral contraceptives differing in progestogen compound on coagulation and fibrinolytic risk variables for venous and arterial thromboembolic diseases. Fibrinolysis and Disease, Molecular and Hemovascular Aspects of Fibrinolysis, P. Glas-Greenwalt. CRC Press. 1995; 226–34, Chapter 32
   Google Scholar
• Mackie I. J., Segal H., Burren T., Gallimore M., Walshe K. J., Robinson G., Machin S. J. Heparin cofactor II levels are increased by the use of combined oral contraceptives. Blood Coagul Fibrinol 1991; 1: 647–51
   Google Scholar
• Daly L., Bonnar J. Comparative studies of 30 μg ethinyl estradiol combined with gestodene and desogestrel on blood coagulation, fibrinolysis and platelets. Am. J. Obstet. Gynecol 1990; 163: 430–7
   PubMed Web of Science ®Google Scholar
• Bonnar J. Changes in coagulation and fibrinolysis with low dose oral contraceptives. Adv. Contracept. 1991; 7(Suppl. 3)285–91
   Google Scholar
• Winkler U. H., Koslowski S., Oberhoff C., Schindler E. M., Schindler A. E. Changes of the dynamic equilibrium of hemostasis associated with the use of low-dose oral contraceptives: a controlled study of cyproterone acetate containing oral contraceptives combined with either 35 or 50 μg ethinyl estradiol. Adv. Contracept. 1991; 7(Suppl. 3)273–84
   Google Scholar
• Campbell S. J., Mackie I. J., Robinson G. E., Machin S. J. Contact factor mediated fibrinolysis is increased by the combined oral contraceptive pill. Br. J. Obstet., Gynaecol. 1993; 100: 79–84
   Google Scholar
• Petersen K. R., Skouby S. O., Sidelmann J., Mølsted-Pedersen L., Jespersen J. Effects of contraceptive steroids on cardiovascular risk factors in women with insulin-dependent diabetes mellitus. Am. J. Obstet. Gynecol 1994; 171: 400–5
   Google Scholar
• Nieuwenhuizen W. Soluble fibrin as a molecular marker for a pre-thrombotic state: a mini-review. Blood Coagul. Fibrinol 1993; 4: 93–6
   Google Scholar
• Nossel H. L. Relative proteolysis of the fibrinogen B β-chain by thrombin and plasmin as a determinant of thrombosis. Nature 1981; 291: 165–7
   PubMed Web of Science ®Google Scholar
• Gram J., Munkvad S., Jespersen J. Enhanced generation and resolution of fibrin in women above the age of 30 years using oral contraceptives low in estrogen. Am. J. Obstet. Gynecol 1990; 163: 438–42
   Google Scholar
• Mannucci P. M., Tripodi A., Bottasso B., Baudo F., Finazzi G., De-Stefano V., Palareti G., Manotti C., Mazzucconi M. G., Castaman G. Markers of procoagulant imbalance in patients with inherited thrombophilic syndromes. Thromb. Haemostas. 1992; 67: 200–2
   PubMed Web of Science ®Google Scholar
• David J. L., Demeyer F., Gillain D., Gaspard U. Haemostasis global profile during monophasic oral contraception by norgestimate or desogestrel associated to low-dose ethinylestradiol. Gynecol. Endocrinol 1996; 10(Suppl. 2)137–9
   Google Scholar
• Schrauwen Y., de Vries R. E.M., Kooistra T., Emeis J. J. Acute release of tissue-type plasminogen activator (t-PA) from the endothelium; regulatory mechanisms and therapeutic target. Fibrinolysis 1994; 8(Suppl. 2)8–12
   Google Scholar
• Brussaard H. E., Gevers Leuven J. A., Emeis J. J., Kluft C., Krans H. M.J. Effect of short term postmenopausal estrogen replacement therapy in women with non-insulin dependent diabetes mellitus on endothelial function variables in blood. Gynecol. Endocrinol. 1996; 10(Suppl. 2)173–7
   Google Scholar